A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Trial Profile

A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Venetoclax (Primary) ; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 25 Jun 2017 Results assessing minimal residual disease in bone marrow (n=49) presented at the 22nd Congress of the European Haematology Association.
    • 23 Jun 2017 According to an AbbVie media release, results from this study presented at the 22nd European Hematology Association (EHA) Annual Congress.
    • 23 Jun 2017 Results (n=49) from this study published in an AbbVie Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top